First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer von Shaw, Alice T, Bauer, Todd M, de Marinis, Filippo, Felip, Enriqueta, Goto, Yasushi, Liu, Geoffrey, Mazieres, Julien, Kim, Dong-Wan, Mok, Tony, Polli, Anna, Thurm, Holger, Calella, Anna M, Peltz, Gerson, Solomon, Benjamin J

Volltext

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer von Solomon, Benjamin J, Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Tursi, Jennifer, Blackhall, Fiona

Volltext

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer von Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

Volltext

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma von Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia, Pardo, Nuria, Cedrés, Susana, Fan, Cheng, Parker, Joel S, Gaba, Lydia, Victoria, Iván, Viñolas, Nuria, Vivancos, Ana, Arance, Ana, Felip, Enriqueta

Volltext

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC von Herbst, Roy S, Giaccone, Giuseppe, de Marinis, Filippo, Reinmuth, Niels, Vergnenegre, Alain, Barrios, Carlos H, Morise, Masahiro, Felip, Enriqueta, Andric, Zoran, Geater, Sarayut, Özgüroğlu, Mustafa, Zou, Wei, Sandler, Alan, Enquist, Ida, Komatsubara, Kimberly, Deng, Yu, Kuriki, Hiroshi, Wen, Xiaohui, McCleland, Mark, Mocci, Simonetta, Jassem, Jacek, Spigel, David R

Volltext

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer von Gadgeel, Shirish, Rodriguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Domine, Manuel, Hui, Rina, Hochmair, Maximilian J., Clingan, Philip, Powell, Steven F., Cheng, Susanna Yee-Shan, Bischoff, Helge G., Peled, Nir, Grossi, Francesco, Jennens, Ross R., Reck, Martin, Garon, Edward B., Novello, Silvia, Rubio-Viqueira, Belen, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E., Yang, Jing, Bas, Tuba, Pietanza, M. Catherine, Garassino, Marina C.

Volltext

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer von Solomon, Benjamin J, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Tang, Yiyun, Wilner, Keith D, Blackhall, Fiona, Mok, Tony S

Volltext

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer von Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

Volltext

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James Chih-Hsin, Han, Ji-Youn, Lee, Jong-Seok, Hochmair, Maximilian J, Li, Jacky Yu-Chung, Chang, Gee-Chen, Lee, Ki Hyeong, Gridelli, Cesare, Delmonte, Angelo, Garcia Campelo, Rosario, Kim, Dong-Wan, Bearz, Alessandra, Griesinger, Frank, Morabito, Alessandro, Felip, Enriqueta, Califano, Raffaele, Ghosh, Sharmistha, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Gupta, Neeraj, Haney, Jeff, Kerstein, David, Popat, Sanjay

Volltext

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M von Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R

Volltext

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer von Borghaei, Hossein, Paz-Ares, Luis, Horn, Leora, Spigel, David R, Steins, Martin, Ready, Neal E, Chow, Laura Q, Vokes, Everett E, Felip, Enriqueta, Holgado, Esther, Barlesi, Fabrice, Kohlhäufl, Martin, Arrieta, Oscar, Burgio, Marco Angelo, Fayette, Jérôme, Lena, Hervé, Poddubskaya, Elena, Gerber, David E, Gettinger, Scott N, Rudin, Charles M, Rizvi, Naiyer, Crinò, Lucio, Blumenschein, George R, Antonia, Scott J, Dorange, Cécile, Harbison, Christopher T, Graf Finckenstein, Friedrich, Brahmer, Julie R

Volltext

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer von Wolf, Jürgen, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B, Groen, Harry J.M, Tan, Daniel S.W, Hida, Toyoaki, de Jonge, Maja, Orlov, Sergey V, Smit, Egbert F, Souquet, Pierre-Jean, Vansteenkiste, Johan, Hochmair, Maximilian, Felip, Enriqueta, Nishio, Makoto, Thomas, Michael, Ohashi, Kadoaki, Toyozawa, Ryo, Overbeck, Tobias R, de Marinis, Filippo, Kim, Tae-Min, Laack, Eckart, Robeva, Anna, Le Mouhaer, Sylvie, Waldron-Lynch, Maeve, Sankaran, Banu, Balbin, O. Alejandro, Cui, Xiaoming, Giovannini, Monica, Akimov, Mikhail, Heist, Rebecca S

Volltext

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations von Paik, Paul K, Felip, Enriqueta, Veillon, Remi, Sakai, Hiroshi, Cortot, Alexis B, Garassino, Marina C, Mazieres, Julien, Viteri, Santiago, Senellart, Helene, Van Meerbeeck, Jan, Raskin, Jo, Reinmuth, Niels, Conte, Pierfranco, Kowalski, Dariusz, Cho, Byoung Chul, Patel, Jyoti D, Horn, Leora, Griesinger, Frank, Han, Ji-Youn, Kim, Young-Chul, Chang, Gee-Chen, Tsai, Chen-Liang, Yang, James C.-H, Chen, Yuh-Min, Smit, Egbert F, van der Wekken, Anthonie J, Kato, Terufumi, Juraeva, Dilafruz, Stroh, Christopher, Bruns, Rolf, Straub, Josef, Johne, Andreas, Scheele, Jürgen, Heymach, John V, Le, Xiuning

Volltext

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial von Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Gupta, Neeraj, Hanley, Michael J., Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay

Volltext

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer von Garon, Edward B, Rizvi, Naiyer A, Hui, Rina, Leighl, Natasha, Balmanoukian, Ani S, Eder, Joseph Paul, Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew, Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Hellmann, Matthew D, Hamid, Omid, Goldman, Jonathan W, Soria, Jean-Charles, Dolled-Filhart, Marisa, Rutledge, Ruth Z, Zhang, Jin, Lunceford, Jared K, Rangwala, Reshma, Lubiniecki, Gregory M, Roach, Charlotte, Emancipator, Kenneth, Gandhi, Leena

Volltext

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer von Reck, Martin, Luft, Alexander, Szczesna, Aleksandra, Havel, Libor, Kim, Sang-We, Akerley, Wallace, Pietanza, Maria Catherine, Wu, Yi-Long, Zielinski, Christoph, Thomas, Michael, Felip, Enriqueta, Gold, Kathryn, Horn, Leora, Aerts, Joachim, Nakagawa, Kazuhiko, Lorigan, Paul, Pieters, Anne, Kong Sanchez, Teresa, Fairchild, Justin, Spigel, David

Volltext

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours von Fernandes Neto, João M., Nadal, Ernest, Bosdriesz, Evert, Ooft, Salo N., Farre, Lourdes, McLean, Chelsea, Klarenbeek, Sjoerd, Jurgens, Anouk, Hagen, Hannes, Wang, Liqin, Felip, Enriqueta, Martinez-Marti, Alex, Vidal, August, Voest, Emile, Wessels, Lodewyk F. A., van Tellingen, Olaf, Villanueva, Alberto, Bernards, René

Volltext

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer von Shaw, Alice T, Solomon, Benjamin J, Besse, Benjamin, Bauer, Todd M, Lin, Chia-Chi, Soo, Ross A, Riely, Gregory J, Ou, Sai-Hong Ignatius, Clancy, Jill S, Li, Sherry, Abbattista, Antonello, Thurm, Holger, Satouchi, Miyako, Camidge, D Ross, Kao, Steven, Chiari, Rita, Gadgeel, Shirish M, Felip, Enriqueta, Martini, Jean-François

Volltext

Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-la... von Shaw, Alice T, Dr, Kim, Tae Min, MD, Crinò, Lucio, Prof, Gridelli, Cesare, MD, Kiura, Katsuyuki, MD, Liu, Geoffrey, MD, Novello, Silvia, Prof, Bearz, Alessandra, MD, Gautschi, Oliver, MD, Mok, Tony, Prof, Nishio, Makoto, MD, Scagliotti, Giorgio, Prof, Spigel, David R, MD, Deudon, Stéphanie, PharmD, Zheng, Cheng, PhD, Pantano, Serafino, PhD, Urban, Patrick, MD, Massacesi, Cristian, MD, Viraswami-Appanna, Kalyanee, PhD, Felip, Enriqueta, MD

Volltext

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial von Herbst, Roy S, Prof, Baas, Paul, Prof, Kim, Dong-Wan, MD, Felip, Enriqueta, MD, Pérez-Gracia, José L, MD, Han, Ji-Youn, Prof, Molina, Julian, MD, Kim, Joo-Hang, Prof, Arvis, Catherine Dubos, MD, Ahn, Myung-Ju, Prof, Majem, Margarita, MD, Fidler, Mary J, MD, de Castro, Gilberto, MD, Garrido, Marcelo, MD, Lubiniecki, Gregory M, MD, Shentu, Yue, PhD, Im, Ellie, MD, Dolled-Filhart, Marisa, PhD, Garon, Edward B, MD

Volltext